UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2344-2353

2010

Volltextzugriff (PDF)

Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening

Molecular cancer therapeutics, 2011-04, Vol.10 (4), p.591-602

2011

Volltextzugriff (PDF)

CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Cell reports (Cambridge), 2022-02, Vol.38 (6), p.110351-110351, Article 110351

2022

Volltextzugriff (PDF)

Role for BRG1 in Cell Cycle Control and Tumor Suppression

Molecular and Cellular Biology, 2004-01, Vol.24 (1), p.362-376

2004

Volltextzugriff (PDF)

A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells

PloS one, 2014-11, Vol.9 (11), p.e111714-e111714

2014

Volltextzugriff (PDF)

Replication stress activates DNA polymerase alpha-associated Chk1

Cell cycle (Georgetown, Tex.), 2009-02, Vol.8 (3), p.482-489

2009

Volltextzugriff (PDF)

Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase

Cell cycle (Georgetown, Tex.), 2010-12, Vol.9 (24), p.4876-4883

2010

Volltextzugriff (PDF)

Cyclin E Associates with BAF155 and BRG1, Components of the Mammalian SWI-SNF Complex, and Alters the Ability of BRG1 To Induce Growth Arrest

Molecular and Cellular Biology, 1999-02, Vol.19 (2), p.1460-1469

1999

Volltextzugriff (PDF)

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors

Journal of clinical oncology, 2015-03, Vol.33 (9), p.1060-1066

2015

Volltextzugriff (PDF)

Cyclin E Associates with Components of the Pre-mRNA Splicing Machinery in Mammalian Cells

Molecular and Cellular Biology, 1998-08, Vol.18 (8), p.4526-4536

1998

Volltextzugriff (PDF)

Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors

Cancer cell, 2018-10, Vol.34 (4), p.611-625.e7

2018

Volltextzugriff (PDF)

Identifying transcriptional programs underlying cancer drug response with TraCe-seq

Nature biotechnology, 2022-01, Vol.40 (1), p.86-93

2022

Volltextzugriff (PDF)

Allosteric Inhibitors of the SARS-COV‑2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3

ACS chemical biology, 2024-01, Vol.19 (1), p.22-36

2024

Volltextzugriff (PDF)

Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation

Cell chemical biology, 2023-02, Vol.30 (2), p.175-187.e15

2023

Volltextzugriff (PDF)

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5‑Fluoro-4-(3H)‑quinazolinone Aryl Urea pan-RAF Kinase Inhibitor

Journal of medicinal chemistry, 2021-04, Vol.64 (7), p.3940-3955

2021

Volltextzugriff (PDF)

Abstract 874: Pharmacologically induced RAS-GTP levels and CRAF-BRAF hetero-dimerization drive sensitization to Type II pan-RAF inhibitors in KRAS mutant cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.874-874

2018

Volltextzugriff (PDF)

Abstract 4967: RAF kinase inhibition synergizes with MEK inhibitors in KRAS mutant tumors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4967-4967

2017

Volltextzugriff (PDF)

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

ACS medicinal chemistry letters, 2010-08, Vol.1 (5), p.204-208

2010

Volltextzugriff (PDF)

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor

ACS medicinal chemistry letters, 2021-05, Vol.12 (5), p.791-797

2021

Volltextzugriff (PDF)

BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines

Cancer research (Chicago, Ill.), 2000-11, Vol.60 (21), p.6171-6177

2000

Volltextzugriff (PDF)

The identification of novel 5′-amino gemcitabine analogs as potent RRM1 inhibitors

Bioorganic & medicinal chemistry, 2014-04, Vol.22 (7), p.2303-2310

2014

Volltextzugriff (PDF)

Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II

Oncogene, 1996-06, Vol.12 (12), p.2631-2640

1996

Volltextzugriff (PDF)

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

Bioorganic & medicinal chemistry, 2007-11, Vol.17 (22), p.6216-6219

2007

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(59)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(33)
Humans
(31)
Female
(13)
Animals
(12)
Biochemistry & Molecular Biology
(10)
Cell Line, Tumor
(10)
Mice
(10)
Biological And Medical Sciences
(9)
Cell Biology
(9)
Male
(9)
Molecular Sequence Data
(8)
Multidisciplinary Sciences
(7)
Mutation
(7)
Oncology
(7)
Science & Technology - Other Topics
(7)
Protein Kinase Inhibitors - Pharmacology
(6)
Proteins
(6)
Amino Acid Sequence
(5)
Base Sequence
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor

Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening

CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Role for BRG1 in Cell Cycle Control and Tumor Suppression

A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells

Replication stress activates DNA polymerase alpha-associated Chk1

Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase

Cyclin E Associates with BAF155 and BRG1, Components of the Mammalian SWI-SNF Complex, and Alters the Ability of BRG1 To Induce Growth Arrest

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Cyclin E Associates with Components of the Pre-mRNA Splicing Machinery in Mammalian Cells

Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors

Identifying transcriptional programs underlying cancer drug response with TraCe-seq

Allosteric Inhibitors of the SARS-COV‑2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3

Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5‑Fluoro-4-(3H)‑quinazolinone Aryl Urea pan-RAF Kinase Inhibitor

ARAF mutations confer resistance to the RAF inhibitobelvarafenib in melanoma

Abstract 874: Pharmacologically induced RAS-GTP levels and CRAF-BRAF hetero-dimerization drive sensitization to Type II pan-RAF inhibitors in KRAS mutant cancer

Abstract 4967: RAF kinase inhibition synergizes with MEK inhibitors in KRAS mutant tumors

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor

BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines

The identification of novel 5′-amino gemcitabine analogs as potent RRM1 inhibitors

Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

Suchergebnisse filtern